Study of SHR-A1811 for advanced HER2-positive colorectal cancer
Part of Cancer clinical trials.
This trial tests a new investigational drug called SHR-A1811 for people with advanced colorectal cancer that has some HER2 protein. It is for those who have already tried standard chemotherapy and need another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread or come back and cannot be removed with surgery.
- You have already tried chemotherapy with oxaliplatin and a drug like 5-FU, and your cancer continued to grow.
- Your tumor has some level of HER2 protein (either high or low/moderate).
- You have not had a previous HER2-targeted antibody-drug conjugate (like T-DM1 or Enhertu).
- Your cancer is not the MSI-high (or dMMR) type.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.